Cheng Yi Pharmaceutical (603811) announced on the evening of August 24th that the company has recently received a food production license issued by the Zhejiang Provincial Market Supervision Administration, classified as health food. According to the announcement, the production workshop for the health food production license certification is the health food soft capsule production workshop, with a cumulative investment of approximately 31.73 million yuan (unaudited) in the production line, and a designed production capacity of 500 million capsules. The main production product is fish oil soft capsules.
It is understood that Cheng Yi Pharmaceutical will focus on promoting the "Two Strong and One Large" strategy during the 14th Five Year Plan period. "Two Strong" refers to strengthening the ammonia sugar industry and ultra-high purity EPA fish oil industry, and "One Large" refers to continuing to expand the "big health industry". The Dongtou District in Wenzhou, where the company is located, is rich in marine resources. With the support of national policies to strengthen marine resource development, promote marine biotechnology research and industrialization, the company continues to develop marine drugs and health products.
In July of this year, Cheng Yi Pharmaceutical completed the registration of two fish oil soft capsule products for domestic health food and obtained the registration certificate for domestic health food issued by the State Administration for Market Regulation. This year, Cheng Yi Pharmaceutical is expected to form a production capacity of 100 tons of ultra-high purity fish oil EPA.
Cheng Yi Pharmaceutical stated that the formal production of the company's health food soft capsule workshop will be conducive to further increasing the company's product categories, enriching the company's product line, enhancing the company's health food field, in line with the company's strategic plan to layout the big health industry, and laying a foundation for the continuous development of the enterprise.
In addition to fish oil soft capsules, Cheng Yi Pharmaceutical is promoting the commercialization and industrialization of multiple "health series products". Medicines and health foods represented by Dendrobium officinale have been successfully developed and listed in a subsidiary in Yunnan; The development and production of ultrahigh purity "nervonic acid" to protect brain health has been successfully trial produced.
It is worth mentioning that Cheng Yi Pharmaceutical invested 24.8983 million yuan in research and development in the first half of 2022, a year-on-year increase of 25%. Since 2019, the company has invested over 125 million yuan in research and development.
Article source: https://wap.egsea.com/detail/article?id=1255812